miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glioma is the most common type of primary malignant brain tumor in adults. Our previous work discovered that plasma miR-454-3p may have some advantages in glioma prognosis, but the clinical significance and the regulatory mechanism of miR-454-3p in glioma have not been systematically investigated, especially regarding the relationship between circulating and tissue miR-454-3p. The expression level of miR-454-3p in glioma serum and tissues was analyzed through quantitative real-time PCR (qRT-PCR). Cell-Counting Kit 8 (CCK-8), wound healing, transwell invasion, apoptosis, and immunofluorescence assays were used to assess the role of miR-454-3p in glioma cancer cells. ATG12 was selected as the target gene of miR-454-3p by bioinformatic analysis. The relationship between ATG12 and miR-454-3p was further validated by luciferase reporter assays and Western blot analysis. miR-454-3p was significantly downregulated in tumor tissues, while it was remarkably upregulated in exosomes from the same patients with glioma. The area under curve (AUC) of exosomal miR-454-3p for glioma diagnosis was 0.8663. The exosomal miR-454-3p was prominently lower in the postoperative serums than that in the preoperative serums. High miR-454-3p expression in exosomes or low miR-454-3p expression in tissue was associated with poor prognosis. Restored expression of miR-454-3p suppressed cell proliferation, migration, invasion, and autophagy in glioma. ATG12 was validated as a direct target of miR-454-3p. The overexpression of ATG12 could partially reverse the effects induced by miR-454-3p suppression. Our data indicate that miR-454-3p may serve as an exosomal biomarker and may be developed into a novel treatment for glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849 · cited 1×
“html) (19) as shown in Supplementary Fig.”
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
van der Vos, K. E., Abels, E. R., Zhang, X., Lai, C., Carrizosa, E., Oakley, D., Prabhakar, S., Mardini, O., Crommentuijn, M. H. W., Skog, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov244 · Cited by 315 · cited 1×
“For example, miR-21-5p derived from glioblastoma exosomewas uptaken bymicroglia and led to the downregulation of c-Myc mRNA in microglia (45).”
BackgroundmiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2
An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., & Zhao, Q. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.123 · Cited by 218 · cited 1×
“ATG12 is targeted by miR-214 in colorectal cancer (47), by miR-23a in cutaneous melanoma (48), by miR-146a-5p in non–small cell lung cancer (49), and by miR-23b-3p in gastric cancer (50).”
Background
Cited by
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications
Cheng, J., Meng, J., Zhu, L., & Peng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01189-3 · Cited by 319
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
“To prepare for subsequent colonization of the lung tissue by extravasating circulating tumor cells (CTC), the lung microenvironment is remodeled by the activated lung fibroblasts (58).”
BackgroundTherapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer
Avgoulas, D. I., Tasioulis, K. S., Papi, R. M., & Pantazaki, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051439 · Cited by 57
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
Qian, X.-L., Zhou, F., Xu, S., Jiang, J., Chen, Z.-P., Wang, S.-K., Zuo, Y., & Ni, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638537 · Cited by 34
Metadata
- Authors
- Shao, N., Xue, L., Wang, R., Luo, K., Zhi, F., & Lan, Q.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2019-02-01
- Volume
- 18
- Issue
- 2
- Pages
- 459-469
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2900278496
- Cited by
- 95
- References
- 5
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-0725
- The paper
- Shao, N., Xue, L., Wang, R., Luo, K., Zhi, F., & Lan, Q. (2019). miR-454-3p Is an Exosomal Biomarker and Functions as a Tumor Suppressor in Glioma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-0725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.